Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy
Zhan Shi,Sihui Zhu,Yuncheng Jin,Liang Qi,Mingzhen Zhou,Ziyan Zhou,Juan Zhang,Baorui Liu,Jie Shen
DOI: https://doi.org/10.2147/jhc.s452424
2024-02-09
Journal of Hepatocellular Carcinoma
Abstract:Zhan Shi, 1, &ast Sihui Zhu, 2, &ast Yuncheng Jin, 1 Liang Qi, 1 Mingzhen Zhou, 1 Ziyan Zhou, 1 Juan Zhang, 1 Baorui Liu, 1 Jie Shen 1 1 Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu Province, 210008, People's Republic of China; 2 The Comprehensive Cancer Centre of Nanjing International Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Province, 210008, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jie Shen; Baorui Liu, Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu Province, 210008, People's Republic of China, Fax +86-025-83106666, Email ; Background: Stereotactic body radiotherapy (SBRT) has emerged as an alternative approach for patients with hepatocellular carcinoma (HCC), and we aim to find potential prognostic biomarkers for HCC patients who received SBRT. Methods: In this study, we retrospectively analyzed HCC patients who underwent SBRT in our institution from January 2018 to December 2022. The inflammatory parameters, along with baseline patients' characteristics were collected to elucidate the potential relationship with survival benefits and liver toxicities. Results: Overall, 35 patients were enrolled in our study. For the efficacy population (25 patients who underwent SBRT for primary liver lesions), the objective response rate (ORR) and disease control rate (DCR) were 60% and 100%, respectively. The median progression-free survival (PFS) was 9.9 months [95% confidence interval (CI) 5.6– 14.1 months], and the median overall survival (OS) was 18.5 months (95% CI 14.2– 22.8 months). We further confirmed that higher baseline lymphocyte-C-reactive protein ratio (LCR) (≥ 2361.11) was positively related to both longer PFS (12.0 vs 4.3 months, P = 0.002) and OS (21.9 vs 11.4 months, P = 0.022). Moreover, patients with diabetes and higher alpha-fetoprotein (AFP) (≥ 400 ng/mL) were also found to be associated with worse OS. The most common hepatotoxicity was elevated gamma-glutamyl transferase (GGT) (84.0%). Conclusion: In conclusion, for patients with inoperable HCC, SBRT resulted in satisfactory local control, survival benefits, and acceptable liver toxicity. Pre-radiotherapy LCR might be an independent and readily available predictor for survival, which facilitates us to find the most appropriate treatment options. Keywords: hepatocellular carcinoma, stereotactic body radiotherapy, lymphocyte-C-reactive protein ratio, survival, liver toxicity Liver cancer represents the sixth most common malignancy and third lethal cancer-related mortality worldwide, 1 with an estimated 1.4 million new cases and 1.3 million deaths in 2040, 2 in which, hepatocellular carcinoma (HCC) is the most common form. Notably, the aetiology, diagnosis, treatment, and survival have changed during the past decade. 3 Surgical resection, liver transplantation, and local radiofrequency ablation (RFA) are the preferred treatment regimens for early-stage HCC patients. The following locoregional therapies, such as transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy (HAIC), and external beam radiotherapy (EBRT) have become the mainstays for intermediate HCC cases. Additionally, systemic targeted therapy and immunotherapy have shown promising antitumor activity for those who were not candidate for surgery or locoregional interventions. 4 Dual immune-checkpoint inhibitors were also confirmed to be effective and well-tolerance. 5 More recently, camrelizumab (an anti-programmed cell death protein-1 [PD-1] antibody) plus rivoceranib (an anti-angiogenic tyrosine-kinase inhibitor) showed encouraging survival benefits for unresectable HCC. 6 Currently, EBRT, especially for stereotactic body radiotherapy (SBRT), has emerged as an alternative approach to intermediate and advanced HCC, with the advantage of higher precision of radiation delivery, and less toxicity to the surrounding normal tissues, 7 even for those who diagnosed with Barcelona clinical liver cancer (BCLC) stage-C, palliative SBRT is an effective and safe treatment modality. 8 Previous studies have demonstrated the high efficacy and well-tolerance of SBRT alone for the treatment of primary liver cancer, as well as extrahepatic metastases. 9,10 In addition, the Phase 3 clinical trial of -Abstract Truncated-
oncology